| Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines focusing on central nervous system disorders. Co. has a portfolio of product including its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. We show 47 historical shares outstanding datapoints in our ACAD shares outstanding history coverage, used to compute ACAD market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACAD market cap history over the course of time is important for investors
interested in comparing ACAD's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACAD versus a peer is one thing; comparing
ACAD market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACAD can fluctuate over the course of history.
With this page we aim to empower investors researching ACAD by allowing them to research the ACAD market cap history.